LM-108 is under clinical development by LaNova Medicines and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase II drugs for Triple-Negative Breast Cancer (TNBC) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how LM-108’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

LM-108 overview

LM-108 is under development for the treatment of advanced solid tumors, recurrent and metastatic triple – negative breast cancer and pancreatic cancer. The drug candidate is administered through intravenous route. It acts by targeting C-C Chemokine Receptor Type 8.

LaNova Medicines overview

LaNova Medicines (Lanova) is a clinical-stage biotechnology company that discovers and develops antibody-based cancer treatments. The company’s antibody-drug conjugates (ADCs) products pipeline includes LM-302, LM-305, LM-001, LM-002, LM-003, LM-004, LM-005, LM-006, and LM-007. It also develops monoclonal antibodies (mAbs) such as LM-108 and LM-101. Lanova products are used in treating solid tumors, gastrointestinal cancer, multiple myeloma, and hematologic malignancies. The company develops a wide range of tumor-associated antigens (TAA) and immuno-oncology (IO) targets by leveraging its proprietary targeted antibody discovery platform (LX-TAb), next-gen ADC platform (LX-ADC) and immune cell engager platform (LX-TDuo). It works in collaboration with Akesobio, AstraZeneca, Bristol Myers Squibb, Cellular Biomedicine Group (CBMG), and Topalliance Biosciences for clinical development and commercialization. Lanova is headquartered in Shanghai, China.

For a complete picture of LM-108’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.